SFG Wealth Management LLC. Sells 138 Shares of Johnson & Johnson (NYSE:JNJ)

SFG Wealth Management LLC. lowered its stake in Johnson & Johnson (NYSE:JNJ) by 7.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,603 shares of the company’s stock after selling 138 shares during the period. SFG Wealth Management LLC.’s holdings in Johnson & Johnson were worth $232,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. IFS Advisors LLC boosted its position in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares in the last quarter. Highline Wealth Partners LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at about $31,000. RPg Family Wealth Advisory LLC bought a new position in Johnson & Johnson during the 3rd quarter worth approximately $35,000. Mowery & Schoenfeld Wealth Management LLC lifted its holdings in Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after buying an additional 91 shares during the period. Finally, Activest Wealth Management bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $40,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Up 0.7 %

Shares of Johnson & Johnson stock opened at $148.10 on Wednesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The firm has a market cap of $356.57 billion, a PE ratio of 21.43, a PEG ratio of 2.39 and a beta of 0.51. The company has a 50 day simple moving average of $148.35 and a two-hundred day simple moving average of $156.11.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.35%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on JNJ shares. Morgan Stanley raised their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Royal Bank of Canada lifted their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Bank of America decreased their price target on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating for the company in a research report on Friday, January 17th. Wells Fargo & Company boosted their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Barclays decreased their price objective on Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating for the company in a report on Tuesday. Eight analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $173.27.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.